Mankind Pharma Ltd
Metformin (1000mg) + Linagliptin (2.5mg)
Dynaglipt LM 1000mg/2.5mg Tablet is a combination of two medicines that control high blood sugar levels in people with type 2 diabetes mellitus.
Tablet
Dynaglipt LM 1000mg/2.5mg Tablet is a combination of two medicines that control high blood sugar levels in people with type 2 diabetes mellitus. This helps prevent serious complications of diabetes such as kidney damage and blindness and may reduce your chance of having a heart attack or stroke.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Dynaglipt LM 1000mg/2.5mg Tablet is to be taken with food.
No common side effects listed.
It is unsafe to consume alcohol with Dynaglipt LM 1000mg/2.5mg Tablet.
Dynaglipt LM 1000mg/2.5mg Tablet is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
Dynaglipt LM 1000mg/2.5mg Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
Dynaglipt LM 1000mg/2.5mg Tablet is a combination of two antidiabetic medicines:
Dynaglipt LM 1000mg/2.5mg Tablet should be taken with food to lower the chances of having an upset stomach. Take it in addition to regular exercise and a healthy diet to lower the levels of blood sugar. Chances of weight gain and low blood sugar are lesser as compared to other diabetes medicines. Hypoglycemia (low blood sugar level) may occur when taken along with other antidiabetic medicines, alcohol or on delaying/skipping a meal. Carry a sugar source with you for immediate relief. Monitor your blood sugar level regularly while you are taking this medicine. Inform your doctor about your diabetes treatment if you are due to have any surgery under a general anaesthetic. Tell your doctor immediately if you experience any deep or rapid breathing, persistent nausea, vomiting or stomach pain as Dynaglipt LM 1000mg/2.5mg Tablet may cause a rare but serious condition called lactic acidosis which is an excess of lactic acid in the blood.
Yes, Dynaglipt LM 1000mg/2.5mg Tablet can cause lactic acidosis, also known as MALA (Metformin-associated lactic acidosis). It is a rare side effect associated with metformin use and requires careful consideration in patients with underlying conditions.
Possible side effects include hypoglycemia (low blood sugar), altered taste, nausea, stomach pain, diarrhea, and headache. It is important to be aware that it may also contribute to lactic acidosis, especially in patients with underlying conditions such as kidney disease or liver impairment.
Individuals with known allergies to any of the ingredients in this medicine should avoid use. Use should also be avoided for patients with severe kidney impairment, liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
No, consuming alcohol alongside Dynaglipt LM 1000mg/2.5mg Tablet is not recommended due to the increased risk of lactic acidosis, particularly in cases of fasting, malnutrition, or kidney dysfunction.
Store this medicine in its original packaging, tightly closed, according to the instructions on the package or label. Dispose of any unused medication appropriately, ensuring it is not accessible to pets, children, or others.
While this medicine itself usually does not cause hypoglycemia, it could potentially occur if there is insufficient calorie intake while taking the medication. Symptoms of hypoglycemia include nausea, headache, irritability, hunger, sweating, dizziness, fast heart rate, and anxiety or shakiness. This may be more likely to happen if you miss meals, consume alcohol, over-exercise, or use other antidiabetic medications alongside it. It is crucial to monitor blood sugar levels regularly.
Yes, long-term usage of Dynaglipt LM 1000mg/2.5mg Tablet can potentially cause vitamin B12 deficiency due to its impact on stomach absorption.